To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
Theme 3: Validate clinical effectiveness of new agents and new protocols in interventional treatment trials
In preclinical triple-negative breast cancer (TNBC) models, Drs. Boerner, Polin and Heilbrun, working with Dr. LoRusso, found that poly (ADP-ribose) polymerase (PARP) inhibitors such as veliparib (ABT-888) enhanced the activity of the topoisomerase 1 inhibitor irinotecan (CPT-11). Based on these results, a Phase I clinical trial was performed to examine the tolerability of combined veliparib/ironotecan in advanced solid tumor patients. Following the dose-escalation phase, an expansion cohort was opened to perform further biomarker and genomic correlative studies in two specific TNBC populations with the combined veliparib/irinotecan.
Dr. Gadgeelwas a Principal Investigators on a phase I/II study evaluating CH5424802 (alectinib), a second generation ALK (anaplastic lymphoma kinase) inhibitor in patients with ALK positive NSCLC (non-small cell lung cancer) whose disease had progressed following treatment with the first generation ALK inhibitor crizotinib. Based on the results of the phase II trial, the drug has received ‘breakthrough designation’ by the US FDA.
Steve Thomashefski got prostate cancer screenings regularly for years, then one day, his doctor surprised him. “My doctor said there was a chance ...
Parade Latonya Riddle-Jones, M.D., MPH, internist, pediatrician, and associate director for Diversity, Equity and Inclusion at Karmanos, explained...
Parade Latonya Riddle-Jones, M.D., MPH, internist, pediatrician, and associate director for Diversity, Equity and Inclusion at Karmanos, shared th...